Anteris Technologies

We are committed to moving the conversation forward in TAVR and have partnered with experts in 4D MRI to study the flow patterns post-TAVR compared to the healthy aortic valve. Restoration of laminar flow is associated with favorable reverse remodeling.(1) Listen to Dr. João Cavalcante’s presentation on flow patterns and restoration of laminar flow with the novel DurAVR™ valve: https://lnkd.in/gN-5yW_g #laminarflow #4DMRI #TAVR #TAVI 1. Cavalcante J. Biomimetic Design Restores Flow and Hemodynamics and Leads to Significant LV Mass Regression: update from First-in-Human (FIH) Study with novel DurAVR™ Transcatheter Heart Valve. Oral Presentation at: New York Valves; June 2024; New York, New York. DurAVR™ INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.  

We are pleased to announce that the concept lock for VClip™, a mitral and tricuspid repair device, has been locked in! After a successful animal study, Anteris Technologies and partner v2vmedtech will continue advancing the product toward a first-in-human study. Dr. Vinayak Bapat, CMO v2vmedtech, inc., commented, “Today’s concept lock provides us important proof of concept data. Working closely with engineers and leading interventional cardiologists has allowed us to proceed rapidly as we drive innovation in the TEER space.” At Anteris, we believe collaborating with key physicians and institutions enables us to develop disruptive technologies for valve repair in order to bring better outcomes to patients and their physicians. #MitralRegurgitation #TricuspidRegurgitation #TEER #ValveRepair #ProudtobeAnteris

Did you miss our latest announcement? Last week we announced new data from the DurAVR™ First-in-Human Study (FIH). The latest cohort of 13 patients was undertaken to finalize and confirm the performance of the ComASUR™ Delivery System prior to commencement of the DurAVR THV pivotal, registration study (Phase 3). The 30-day data from this recent cohort demonstrated improved hemodynamic performance relative to earlier favorable clinical results reported in the FIH Study (Cohorts 1-4), in addition to validating the predictability of the ComASUR Delivery System. Read more: https://lnkd.in/ggjkvRVs

Hemodynamic performance is a function of valve design, not delivery method. DurAVR™ THV, a balloon-expandable valve, is demonstrating fantastic hemodynamic performance from EFS and FIH studies. We prioritized hemodynamic performance of DurAVR THV by innovating with a single-piece, biomimetic design that facilitates native-like flow. Learn more: https://lnkd.in/gN8PeEQp DurAVR™ INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

We enjoyed engaging with many of you at New York Valves! In case you missed our symposium, you can now watch the full recording here: https://bit.ly/3Rtt1EW Learn about: 💡The biomimetic DurAVR™ THV, shown to restore laminar blood flow through the valve. 💡The latest imaging techniques for assessing laminar blood flow and the data used to measure the impact. At Anteris, we believe that in order to mimic the performance of a healthy aortic valve, the replacement valve should be designed like a native valve. We are dedicated to moving the conversation forward in TAVR, expanding valve science beyond traditional measures like EOA and MPG, and exploring new metrics and their impact on outcomes. #NYValves2024 #TAVI #TAVR #laminarflow DurAVR™ INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

We are excited to share the promising results from a valve-in-valve (ViV) study led by Dr. Anita Asgar and recently presented at New York Valves. The data demonstrated restoration of hemodynamic performance in five complex cases in which patients underwent a DurAVR™ transcatheter heart valve implantation after their surgical replacement valves failed. Dr. Asgar emphasized, “This data set of valve-in-valve patients highlights the impact of the DurAVR valve biomimetic design by restoring these patients’ hemodynamics to the performance of their initial surgical valve and is very encouraging for the wave of valve-in-valve patients that are coming in the future.” #NYValves2024 #TAVI #TAVR #aorticstenosis #ValveinValve #ViV DurAVR™ INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

We are pleased to announce new DurAVR™ THV First-in-Human study data was presented at New York Valves by imaging expert Dr. João Cavalcante. “When we look at commercially available surgical or TAVR valves, we are still seeing abnormal flow patterns on cardiac MRI. The restoration of laminar flow, as we are seeing with this new DurAVR THV, is a byproduct of the intrinsic valve design and novel technology, which might have positive downstream implications to the arteries and consequently to ventricle, and ultimately to the patients,” stated Dr. Cavalcante. Click to read the full press release: https://lnkd.in/gZAzEVwt #NYValves2024 #TAVI #TAVR #laminarflow

We are pleased to announce that the recording of our recent Annual General Meeting (AGM) is now available for viewing. This comprehensive session includes detailed discussions, strategic updates, and future plans that underscore the continued growth and innovation at Anteris Technologies. Watch the AGM recording here ➡ https://lnkd.in/gWDR_5By We invite all stakeholders, partners, and interested parties to watch this recording to stay informed about our latest developments and achievements. Your continued support and engagement are greatly appreciated. #ProudtobeAnteris #AGM2024 #Innovation

We had great discussions in our packed lunch symposium at New York Valves! Presenters and audience members discussed biomimetic valve design, hemodynamics, and flow dynamics. At Anteris, we believe that in order to mimic the performance of a healthy aortic valve, the replacement valve should be designed like a native valve. This led us to develop a new class of TAVR, a biomimetic valve that is constructed from a single piece of anti-calcification tissue, molded to be native-shaped. DurAVR™ THV is the first and only #TAVR valve to demonstrate laminar flow, both on echo and CMR. We are excited about the promising results from the US Early Feasibility Study and First-in-Human study and are preparing for a larger pivotal trial. Learn more about DurAVR THV: https://bit.ly/3QYCqnw #NYValves2024 #TAVI #aorticstenosis #laminarflow DurAVR™ INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

One more day! Join us for a lunch symposium tomorrow at New York Valves! Don’t miss the opportunity to hear from leading experts about new valve performance parameters with clinical implications and a new class of TAVR designed to restore native flow. Click here to add to your calendar ➡ https://bit.ly/3QYCqnw #NYVALVES2024 DurAVR™ INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.